Baseline characteristics of the three treatment groups.

*<p>Probability values are determined using the χ² test or by analysis of variance as appropriate. The three-way determinations compared the distribution of variables between all three treatment groups and the two-way determinations between the EGb761® and piracetam groups only.</p

Comparison of change in cognitive outcomes over twenty years in the PAQUID cohort between the EGb761® (n = 589) and piracetam treatment (n = 149) groups (mixed linear effects model).

1<p>Covariates: age, gender, educational level, MMSE score at inclusion, depressive symptomatology and memory complaints.</p

Selection of the study sample from the PAQUID cohort.

<p>Selection of the study sample from the PAQUID cohort.</p

Comparison of change in cognitive outcomes over twenty years in the PAQUID cohort in subjects receiving EGb761® (n = 589) or piracetam (n = 149) compared to the ‘neither treatment’ group (n = 2874) (mixed linear effects model).

1<p>Covariates: age, gender, educational level, MMSE score at inclusion, depressive symptomatology and memory complaints.</p

Estimated change in MMSE score over the twenty-year follow-up period in the three treatment groups.

<p>Legend: —— Neither treatment (n = 2874 at inclusion). – – – – EGb761® (n = 589 at inclusion). –·–·– Piracetam (n = 149 at inclusion).</p

Means and standard deviations for the three cognitive scores at each follow-up visit for the three treatment groups.

<p>Means and standard deviations for the three cognitive scores at each follow-up visit for the three treatment groups.</p

Multivariate associations^* between skin AF and prevalent and incident frailty and its components, the Three-City Study, Bordeaux.

<p>Multivariate associations^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0186087#t004fn002" target="_blank">*</a>} between skin AF and prevalent and incident frailty and its components, the Three-City Study, Bordeaux.</p

Flowchart of the study participants.

<p><b>Abbreviations</b>: eGFR: estimated glomerular filtration rate; BP: blood pressure; HT: hypertension; aTRH: apparent treatment-resistant hypertension; cHT: controlled HT; ucHT: uncontrolled hypertension with ≤ 2 antihypertensive drugs; Persistent cHT: controlled hypertension during the 4-year follow-up; Persistent ucHT: uncontrolled hypertension with ≤ 2 antihypertensive drugs during the 4-year follow-up.</p

Skin autofluorescence based on prevalent and incident frailty and its components, the Three-City study, Bordeaux, 2009–2010.

<p>Skin autofluorescence based on prevalent and incident frailty and its components, the Three-City study, Bordeaux, 2009–2010.</p

Skin autofluorescence based on baseline characteristics of older adults in cross-sectional and prospective analysis samples, the Three-City study, Bordeaux, 2009–2010.

<p>Skin autofluorescence based on baseline characteristics of older adults in cross-sectional and prospective analysis samples, the Three-City study, Bordeaux, 2009–2010.</p